China-originated assets
Greater China to World
Cross-border out-licensing for ADCs, bispecifics, cell therapies, and high-quality clinical programs seeking ex-China or global partners.
Hong Kong (HQ)ShanghaiZurichChicago
Services / Out-Licensing
Service / 02 / 04
Monetize therapeutics and IP through the right global partner.
Partner with Vision Lifesciences to out-license therapeutics, technologies, and IP portfolios to qualified global counterparties. We advise sellers from asset assessment and positioning through buyer outreach, diligence, negotiation, and close.
Process
NDA-first
Buyer Universe
Qualified only
Reach
3 Continents
What we deliverv.2026
- Asset PositioningTranslate the science, indication, and market context into a buyer-ready licensing thesis.
- Targeted OutreachRun confidential buyer campaigns across strategic pharma, specialty pharma, and platform acquirers.
- Value ArchitectureModel upfronts, milestones, royalties, territory splits, and retained rights before terms are tabled.
- Process ControlManage NDA, data room, diligence Q&A, term sheet, and definitive agreement workstreams.
- Negotiation SupportKeep competitive tension, protect optionality, and translate scientific value into executable terms.
Why us
What sellers gain by engaging Vision Lifesciences.
Out-licensing is not a mailing campaign. It is a controlled market process: a sharper asset story, a selective buyer universe, and disciplined negotiation.
01
A selective buyer universe
We build a focused counterparty map around therapeutic fit, territory interest, portfolio gaps, and active BD appetite, then approach principals bilaterally.
02
A cleaner asset story
Out-licensing depends on clarity. We pressure-test claims, remove noise, and prepare a concise package that survives scientific, commercial, and IP diligence.
03
Negotiation without leakage
NDA-first process design, controlled disclosure, and disciplined follow-up protect the seller while maintaining competitive tension through term sheet.
Approach
How our out-licensing process works.
From asset assessment to definitive documents, we guide sellers through every stage of a global out-licensing process.
01
Asset Assessment
We review the asset, indication, IP position, development stage, and available data to identify what is genuinely licensable.
02
Positioning & Materials
We shape the non-confidential story, confidential teaser, data-room structure, and diligence narrative for qualified buyers.
03
Partner Campaign
We identify and approach buyers with matching portfolio needs, geography focus, and deal appetite.
04
Terms & Close
We coordinate Q&A, drive term-sheet comparison, support negotiation, and manage the path to definitive documents.
Readiness framework
Six questions every qualified buyer will ask.
We prepare the asset for diligence before the market sees it. The result is a cleaner process, fewer avoidable delays, and stronger negotiating posture.
/ 01
Scientific
Target rationale, mechanism, translatability, differentiation, and known limitations.
/ 02
Clinical
Trial design, patient population, endpoints, safety signal, and data maturity.
/ 03
Commercial
Indication sizing, standard of care, competitive pipeline, payer context, and launch path.
/ 04
IP & Control
Patent estate, ownership chain, freedom-to-operate, encumbrances, and retained-rights constraints.
/ 05
CMC
Manufacturing readiness, tech-transfer complexity, supply chain, and quality documentation.
/ 06
Partner Fit
Buyer strategy, regional capability, development capacity, and cultural execution risk.
Campaigns
Where buyer interest is most active.
We design out-licensing campaigns around real buyer demand, not generic coverage lists. The strongest corridors vary by modality and territory.
EU specialty therapeutics
Europe to USA / Asia
Rare disease, specialty pharma, and platform assets that need a commercial partner or regional development sponsor.
US biotech programs
USA to Global
Early- and mid-stage biotech assets where a selective out-licensing process can fund the next value inflection without forcing a full sale.
Structures
Deal architectures we commonly advise on.
Seller value is shaped by territory, retained rights, development obligations, and closing certainty. Splits below are illustrative; bespoke structures are common.
Territory split
Regional license
Rights licensed by geography, often ex-China, Japan, EU, or North America. Useful when local development or commercial infrastructure is the bottleneck.
Single licensee
Global license
A full global package where the buyer assumes development and commercialization responsibility across major markets.
Data-triggered
Option-to-license
Buyer funds or monitors the next value inflection before exercising rights. Useful for earlier clinical or platform programs.
Shared execution
Co-development
Parties share development obligations, territory rights, or profit participation where both sides bring meaningful capabilities.
Coverage
Therapeutic areas where we operate.
Sell-side coverage spans modalities and indications. The intersections below are where buyer conversations are most active.
Oncology
Immunology
Metabolic
CNS
Rare
Dx
ADC / Bispecific
Small molecule
Biologics
Cell & Gene
Peptide / RNA
Devices & Dx
Illustrative engagements
What an out-licensing mandate looks like.
Anonymized vignettes drawn from past sell-side licensing engagements. Specific counterparties, indications, and economics are confidential and subject to NDA.
Greater China / ex-China rightsCONFIDENTIAL / NDA
Clinical-stage biotech / oncology
BriefCompany needed to monetize a Phase II oncology asset without revealing sponsor identity broadly across the market.
Our roleBuilt anonymized teaser, qualified 24 potential buyers, managed NDA access for 7, and maintained competitive tension through term sheet.
OutcomeEx-China license signed with upfront, development milestones, and tiered royalties.
EU / global development partnerCONFIDENTIAL / NDA
Academic spin-out / rare disease
BriefSpin-out required a partner with clinical development infrastructure but wanted to retain scientific participation.
Our rolePrepared the data room, screened specialist buyers, and structured an option-to-license with development funding.
OutcomeOption agreement executed; next clinical milestone funded by partner.
USA / regional carve-outCONFIDENTIAL / NDA
Mid-sized pharma / non-core portfolio
BriefSeller wanted to out-license a non-core commercial asset while retaining strategic territories.
Our roleSegmented buyers by regional capability, modeled territory economics, and supported definitive agreement negotiation.
OutcomeRegional rights licensed while seller retained priority markets.
Engagement model
Confidentiality is built into the process.
Sellers need market access without uncontrolled leakage. We run selective processes with tight disclosure, clear accountability, and partner-level negotiation support.
Confidential first screen
We pressure-test the asset and seller goals before any external disclosure. If the market is unlikely to respond, we say that clearly.
Controlled buyer process
Outreach is sequenced, tracked, and limited to qualified counterparties. Counterparty identity, data access, and Q&A are managed tightly.
Deal-comparison discipline
We compare offers across economics, obligations, territories, diligence risk, and closing certainty, not just headline upfront.
No handoff at signing
We stay involved through early post-signing handover, including JSC setup, tech-transfer milestones, and operational transition where needed.
Frequently asked
What sellers ask before engaging.
01When should a company start an out-licensing process?+
The best timing is usually before a financing or development inflection forces urgency. We often begin when there is enough data to support differentiated value, but before the seller is locked into one funding path.
02Do you contact buyers before an NDA?+
Initial outreach is non-confidential and anonymized unless the seller authorizes otherwise. Buyer identity and data-room access are controlled through NDA and qualification steps.
03How do you decide which buyers to approach?+
We map counterparties by therapeutic focus, portfolio gaps, territory capability, recent deal appetite, and likely diligence burden. The goal is not a long list; it is the right list.
04Can you support China-originated out-licensing?+
Yes. Greater China to global out-licensing is one of the most active corridors we cover, particularly in oncology, immunology, metabolic disease, and cell therapy.
05How are out-licensing engagements priced?+
Engagements are generally structured with a retainer and success component aligned to signing. The exact structure depends on asset stage, geography, mandate scope, and process complexity.
Engage
Share an asset brief under NDA.
Send the asset, indication, development stage, and target territory profile. A partner will respond within one business day with a confidential first conversation.
RESPONSE WITHIN 24 HOURS / NDA-FIRST